ライフサイエンスコーパス: glucagon-like peptide

1 11%, P = 0.002), NEFA (-21%, P = 0.009), and glucagon-like peptide 1 (-31%, P = 0.001) areas under th

2 w focuses on two peptide drugs - insulin and glucagon-like peptide 1 (GLP-1) - for treatment of type

3 fy 37 T2D patients who were actively using a Glucagon-like peptide 1 (GLP-1) agonist in addition to a

4 Glucagon-like peptide 1 (GLP-1) agonists have shown card

5 The glucagon-like peptide 1 (GLP-1) analog, liraglutide, is

6 Exendin-4 is a long acting glucagon-like peptide 1 (GLP-1) analogue that is an agon

7 ipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) analogues, can increase

8 Glucagon-like peptide 1 (GLP-1) and cholecystokinin (CCK

9 Dual activation of the glucagon-like peptide 1 (GLP-1) and glucagon receptor ha

10 Glucagon-like peptide 1 (GLP-1) and glucagon-like peptid

11 In contrast, AR231453 increased plasma glucagon-like peptide 1 (GLP-1) and insulin levels and i

12 sized that enteroendocrine L-cells producing glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) may

13 ssed on enteroendocrine L cells that release glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) whe

14 Glucagon-like peptide 1 (GLP-1) and serotonin play criti

15 pendent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are secreted postprandia

16 nsulin increased by 120% +/- 15% (P = 0.02), glucagon-like peptide 1 (GLP-1) by 60% +/- 20% (P < 0.01

17 ecretion of the prosurvival incretin hormone glucagon-like peptide 1 (GLP-1) by alpha cells and acts

18 Exocytosis of the hormone glucagon-like peptide 1 (GLP-1) by the intestinal L cell

19 Since glucagon-like peptide 1 (GLP-1) exerts neuroprotective e

20 Therapeutic engineering of glucagon-like peptide 1 (GLP-1) has enabled development

21 Glucagon-like peptide 1 (GLP-1) immunoreactivity of plas

22 The role of intestinally secreted glucagon-like peptide 1 (GLP-1) in regulation of insulin

23 Glucagon-like peptide 1 (GLP-1) is a hormone with essent

24 The gut hormone called glucagon-like peptide 1 (GLP-1) is a strong moderator of

25 e-dependent insulinotropic peptide (GIP) and glucagon-like peptide 1 (GLP-1) is characterized by thei

26 Glucagon-like peptide 1 (GLP-1) is known to suppress glu

27 Glucagon-like peptide 1 (GLP-1) is secreted by intestina

28 The incretin glucagon-like peptide 1 (GLP-1) is secreted by the intes

29 The physiologic properties of glucagon-like peptide 1 (GLP-1) make it a potent candida

30 Glucagon-like peptide 1 (GLP-1) mimetics are effective d

31 Moreover, ANP potentiated the effect of glucagon-like peptide 1 (GLP-1) on glucose-induced insul

32 The glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) is a k

33 armacological activation of the hypothalamic glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) promot

34 Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, and ph

35 Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1

36 Glucagon-like peptide 1 (GLP-1) receptor agonists induce

37 al models of type 2 diabetes have shown that glucagon-like peptide 1 (GLP-1) receptor agonists preven

38 e-18]fluoro-levodopa [(18)F-DOPA] PET-CT and glucagon-like peptide 1 (GLP-1) receptor imaging), and d

39 The glucagon-like peptide 1 (GLP-1) receptor is a class B G

40 Glucagon-like peptide 1 (GLP-1) reduces hyperglucagonemi

41 Glucagon-like peptide 1 (GLP-1) regulates glucose homeos

42 gon released from pancreatic alpha cells and glucagon-like peptide 1 (GLP-1) released from intestinal

43 proposed pathway was not influenced by local glucagon-like peptide 1 (GLP-1) secretion from alpha-cel

44 Glucose is an important stimulus for glucagon-like peptide 1 (GLP-1) secretion, but the mecha

45 in from adipocytes and by those means induce glucagon-like peptide 1 (GLP-1) secretion.

46 Centrally administered glucagon-like peptide 1 (GLP-1) supresses food intake.

47 enhancing the action of the incretin hormone glucagon-like peptide 1 (GLP-1) therapeutically improve

48 This study tested the hypothesis that glucagon-like peptide 1 (GLP-1) therapies improve cardia

49 proof-of-principle, the clinically relevant glucagon-like peptide 1 (GLP-1) was functionalized with

50 ms mediating the cardioprotective actions of glucagon-like peptide 1 (GLP-1) were unknown.

51 ty acids (FFAs), insulin, glucose, glucagon, glucagon-like peptide 1 (GLP-1), and gastric inhibitory

52 in plasma cholecystokinin, peptide YY (PYY), glucagon-like peptide 1 (GLP-1), and glucagon-like pepti

53 ) inhibitor that inhibits the degradation of glucagon-like peptide 1 (GLP-1), and has been approved f

54 peptide YY3-36 (PYY3-36), lithium chloride, glucagon-like peptide 1 (GLP-1), and leptin shows the pr

55 kinin, gastric inhibitory polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and peptide tyrosine ty

56 wn at regular intervals for cholecystokinin, glucagon-like peptide 1 (GLP-1), and peptide YY (PYY) an

57 elated to changes in blood peptide YY (PYY), glucagon-like peptide 1 (GLP-1), glucose, or insulin con

58 ing glucose, lipids (fasting only), insulin, glucagon-like peptide 1 (GLP-1), peptide YY (PYY), and g

59 Fasting and postprandial plasma glucagon-like peptide 1 (GLP-1), peptide YY (PYY), and g

60 RC1), general control nonrepressed 2 (GCN2), glucagon-like peptide 1 (GLP-1), peptide YY (PYY), serot

61 Glucagon-like peptide 1 (GLP-1), secreted from intestina

62 diabetes associated with the stimulation of glucagon-like peptide 1 (GLP-1), which is known to slow

63 Glucagon-like Peptide 1 (GLP-1)-expressing neurons in th

64 S) in the circulation and thereby stimulates glucagon-like peptide 1 (GLP-1)-mediated insulin secreti

65 Here, we present evidence for glucagon-like peptide 1 (GLP-1)-mediated paraventricular

66 studies in subjects with diabetes receiving glucagon-like peptide 1 (GLP-1)-targeted therapies have

67 stimulates secretion of the incretin hormone glucagon-like peptide 1 (GLP-1).

68 elease of the incretin and satiating peptide glucagon-like peptide 1 (GLP-1).

69 tus and obesity, exemplified by the licensed glucagon-like peptide 1 (GLP1) mimetics and dipeptidyl p

70 We describe this method using dulaglutide, a glucagon-like peptide 1 (GLP1)-Fc fusion protein.

71 , dipeptidyl peptidase 4 [DPP-4] inhibitors, glucagon-like peptide 1 [GLP-1] receptor agonists, and s

72 ite-related hormones (active ghrelin, active glucagon-like peptide 1 [GLP-1], total peptide YY [PYY],

73 The cardiovascular effects of semaglutide, a glucagon-like peptide 1 analogue with an extended half-l

74 The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard

75 ontrolled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patien

76 ulation of cells expressing the precursor of glucagon-like peptide 1 and are glutamatergic; able to m

77 with PS-CF and normal control subjects, and glucagon-like peptide 1 and gastric inhibitory polypepti

78 Levels of glucagon-like peptide 1 and gastric inhibitory polypepti

79 Glucagon-like peptide 1 and glucose-dependent insulinotr

80 improves glucose tolerance while stimulating glucagon-like peptide 1 and insulin secretion.

81 ocrine cells (EECs) produce hormones such as glucagon-like peptide 1 and peptide YY that regulate foo

82 Mean changes in serum glucagon-like peptide 1 and peptide YY were 106.6% +/- 2

83 ther dose affected plasma ghrelin, glucagon, glucagon-like peptide 1 and peptide YY, or pyloric and d

84 of 14.6% +/- 2.6% and elevated postprandial glucagon-like peptide 1 compared with controls (49.2 +/-

85 g, enhanced postprandial cholecystokinin and glucagon-like peptide 1 concentrations, and reduced ghre

86 in human beta-cells, using forskolin or the glucagon-like peptide 1 mimetic Exendin-4, inhibits the

87 Strikingly, when P-NT was combined with the glucagon-like peptide 1 mimetic liraglutide, the two pep

88 ted depletion, which could not be rescued by glucagon-like peptide 1 pretreatment.

89 These include biguanides, glucagon-like peptide 1 receptor (GLP-1) agonists, dipep

90 icacy and ability to reduce the body weight, glucagon-like peptide 1 receptor (GLP-1R) agonism has em

91 abetic C57BL/6J mice treated with either the glucagon-like peptide 1 receptor (GLP-1R) agonist liragl

92 Glucagon-like peptide 1 receptor (GLP-1R) agonists are i

93 Glucagon-like peptide 1 receptor (GLP-1R) agonists effec

94 This appeared to be mediated in part by glucagon-like peptide 1 receptor (GLP-1R) and not the G

95 Glucagon-like peptide 1 receptor (GLP-1R) imaging with r

96 The insulinotropic actions of glucagon-like peptide 1 receptor (GLP-1R) in beta-cells

97 like peptide-1 (GLP-1) signaling through the glucagon-like peptide 1 receptor (GLP-1R) is a key regul

98 Glucagon-like peptide 1 receptor (GLP-1R) signaling in t

99 und that exendin-4 (Ex-4), an agonist of the glucagon-like peptide 1 receptor (GLP-1R), stimulates hu

100 gh vagal afferents that require an activated glucagon-like peptide 1 receptor (GLP-1r).

101 DT) with exendin-4-IRDye700DX, targeting the glucagon-like peptide 1 receptor (GLP-1R).

102 ering glucose, incretin drugs, which include glucagon-like peptide 1 receptor (GLP1R) agonists and di

103 Glucagon-like peptide 1 receptor (GLP1R) agonists are wi

104 treatment with thiazolidinedione therapy or glucagon-like peptide 1 receptor agonism alone or in com

105 The short-acting glucagon-like peptide 1 receptor agonist exenatide reduc

106 ctivities of NRTN relative to liraglutide, a glucagon-like peptide 1 receptor agonist, in Zucker diab

107 [(68)Ga]DO3A-VS-Cys(40)-Exendin-4, a glucagon-like peptide 1 receptor agonist, was evaluated

108 odium glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists have consisten

109 Glucagon-like peptide 1 receptors (GLP-1Rs) have been fo

110 In nonfasted rats, central antagonism of glucagon-like peptide 1 receptors partially mimics the e

111 ntragastric infusion test sessions), whereas glucagon-like peptide 1 responses to milkshake intake we

112 enome editing to controllably release GLP-1 (glucagon-like peptide 1), a critical incretin that regul

113 y reports activation in response to insulin, glucagon-like peptide 1, and agents that raise cAMP leve

114 ve for either prolactin-releasing peptide or glucagon-like peptide 1, and attenuates the activation o

115 onists, including ADP, arginine vasopressin, glucagon-like peptide 1, and forskolin, and, surprisingl

116 ut hormones, fibroblast growth factor 19 and glucagon-like peptide 1, and the BA transport systems, a

117 nsional ultrasound), plasma cholecystokinin, glucagon-like peptide 1, glucose-dependent insulinotropi

118 h plasma concentrations of acylated ghrelin, glucagon-like peptide 1, insulin, glucose, and nonesteri

119 accompanied by higher secretion of insulin, glucagon-like peptide 1, peptide YY, and cholecystokinin

120 l motility, plasma ghrelin, cholecystokinin, glucagon-like peptide 1, peptide YY, insulin, glucagon,

121 Based on the success of glucagon-like peptide 1-based therapies for type 2 diabe

122 tidyl-peptidase 4-inhibitor sitagliptin, the glucagon-like peptide 1-receptor agonist lixisenatide ba

123 We assessed the effects of lixisenatide, a glucagon-like peptide 1-receptor agonist, on cardiovascu

124 mentation of fibroblast growth factor 21 and glucagon-like peptide 1.

125 eased gastric volume capacity and release of glucagon-like peptide 1.

126 d improved glucose tolerance, dependent upon glucagon-like peptide 1.

127 es of glucose, insulin, C-peptide, glucagon, glucagon-like peptides 1 and 2, gastric inhibitory pepti

128 udy assessing the occupancy of the dual GCGR/glucagon like peptide-1 receptor agonist SAR425899.

129 Potentiation of glucagon-like peptide-1 (GLP-1) action through selective

130 (OR 0.68, 95% CI 0.58-0.79; p < 0.001), and glucagon-like peptide-1 (GLP-1) agonists (OR 0.37, 95% C

131 Glucagon-like peptide-1 (GLP-1) analogs are approved for

132 dipeptidyl peptidase-4 (DPP4) inhibitors and glucagon-like peptide-1 (GLP-1) analogs, are important n

133 Semaglutide is a once-weekly glucagon-like peptide-1 (GLP-1) analogue for type 2 diab

134 ed the efficacy and safety of semaglutide, a glucagon-like peptide-1 (GLP-1) analogue in clinical dev

135 Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue in phase 3 deve

136 Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to s

137 Glucagon-like peptide-1 (GLP-1) analogues reduce hepatic

138 Glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK

139 ate the anorectic effects of both endogenous glucagon-like peptide-1 (GLP-1) and exogenous GLP-1 rece

140 creting glucagon, insulin, and the incretins glucagon-like peptide-1 (GLP-1) and GIP (glucose-depende

141 Glucagon-like peptide-1 (GLP-1) and glucose-dependent in

142 , Tukey's post hoc, P < 0.05]; and increased glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) com

143 e of enteroendocrine L-cell derived hormones glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) in

144 elease of gastrointestinal peptides, such as glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), fr

145 lation to two clinically important peptides: glucagon-like peptide-1 (GLP-1) and the parathyroid horm

146 circulating glucose, insulin, glucagon, and glucagon-like peptide-1 (GLP-1) concentrations and subje

147 d plasma cholecystokinin (CCK), ghrelin, and glucagon-like peptide-1 (GLP-1) concentrations, appetite

148 We have examined analogues of glucagon-like peptide-1 (GLP-1) containing beta-amino ac

149 red changes in cell health and intracellular glucagon-like peptide-1 (GLP-1) content.

150 The interaction between serotonin (5-HT) and glucagon-like peptide-1 (GLP-1) could play a role as ups

151 Multiple physiological properties of glucagon-like peptide-1 (GLP-1) ensure that it is a prom

152 Pharmacological evidence suggests a role for glucagon-like peptide-1 (GLP-1) in modulating stress res

153 e acid synthesis and intestinal secretion of glucagon-like peptide-1 (GLP-1) in wild-type, Fxr(-/-),

154 Glucagon-like peptide-1 (GLP-1) is a hormone that stimul

155 Glucagon-like peptide-1 (GLP-1) is an incretin hormone w

156 Glucagon-like peptide-1 (GLP-1) is an incretin that play

157 Glucagon-like peptide-1 (GLP-1) is produced in the small

158 The multiple physiological properties of glucagon-like peptide-1 (GLP-1) make it a promising drug

159 Here we show that nicotine activates glucagon-like peptide-1 (GLP-1) neurons in the nucleus t

160 impaired; this impairment is ameliorated by glucagon-like peptide-1 (GLP-1) or by GLP-1 receptor ago

161 Glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonis

162 Glucagon-like peptide-1 (GLP-1) receptor (GLP-1R), gluca

163 Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist adminis

164 Exendin-4 is a glucagon-like peptide-1 (GLP-1) receptor agonist and pot

165 We have generated a humanized glucagon-like peptide-1 (GLP-1) receptor agonist antibod

166 maglutide is the first oral formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist develop

167 d to investigate the association between the glucagon-like peptide-1 (GLP-1) receptor agonist dulaglu

168 Oral semaglutide is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for gly

169 Exendin-4 (EX-4), a glucagon-like peptide-1 (GLP-1) receptor agonist, has be

170 Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has ne

171 exposed to thiazolidinediones (glitazones), glucagon-like peptide-1 (GLP-1) receptor agonists and di

172 Glucagon-like peptide-1 (GLP-1) receptor agonists and so

173 Although glucagon-like peptide-1 (GLP-1) receptor agonists and so

174 Glucagon-like peptide-1 (GLP-1) receptor agonists are ef

175 Glucagon-like peptide-1 (GLP-1) receptor agonists are ef

176 Glucagon-like peptide-1 (GLP-1) receptor agonists are ef

177 Glucagon-like peptide-1 (GLP-1) receptor agonists differ

178 Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce

179 body of preclinical evidence indicates that glucagon-like peptide-1 (GLP-1) receptor agonists reduce

180 Two glucagon-like peptide-1 (GLP-1) receptor agonists reduce

181 amine-norepinephrine reuptake inhibitor, and glucagon-like peptide-1 (GLP-1) receptor agonists.

182 The glucagon-like peptide-1 (GLP-1) receptor and the glucose

183 rlap between signaling and regulation of the glucagon-like peptide-1 (GLP-1) receptor by the non-pept

184 a non-peptide agonist, TT-OAD2, bound to the glucagon-like peptide-1 (GLP-1) receptor.

185 The glucagon-like peptide-1 (GLP-1) receptors are important

186 Recent evidence indicates that activation of glucagon-like peptide-1 (GLP-1) receptors in the ventral

187 The glucagon and glucagon-like peptide-1 (GLP-1) receptors play important

188 oid these systemic effects while stimulating glucagon-like peptide-1 (GLP-1) secreting enteroendocrin

189 021 to be an especially potent stimulator of glucagon-like peptide-1 (GLP-1) secretion in vitro.

190 etate and early-phase insulin, C-peptide and glucagon-like peptide-1 (GLP-1) secretion were increased

191 Glucagon-like peptide-1 (GLP-1) signaling through the gl

192 Alhough the glucagon-like peptide-1 (GLP-1) system is critical to en

193 an 11-residue analogue of the N-terminus of glucagon-like peptide-1 (GLP-1) to investigate effects o

194 lasma levels of insulin, leptin, amylin, and glucagon-like peptide-1 (GLP-1) were assessed using Lumi

195 CK in enteroendocrine cells (EECs) that were glucagon-like peptide-1 (GLP-1)(+)/Peptide YY (PYY(-)) i

196 for their production of the incretin hormone glucagon-like peptide-1 (GLP-1), also release other neur

197 Glucagon-like peptide-1 (GLP-1), an incretin secreted by

198 , we use the validated diabetes therapeutic, glucagon-like peptide-1 (GLP-1), and the target of clini

199 lucose, plasma insulin, C-peptide, glucagon, glucagon-like peptide-1 (GLP-1), glucose-dependent insul

200 bolically-related peptide hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insul

201 FAs and 2-OG, on enteroendocrine secretions [glucagon-like peptide-1 (GLP-1), glucose-dependent insul

202 on of glucose-regulating hormones, including glucagon-like peptide-1 (GLP-1), peptide YY (PYY), and i

203 ll-bowel motility, other MRI parameters, and glucagon-like peptide-1 (GLP-1), polypeptide YY (PYY), a

204 lation of an important pharmaceutical, human glucagon-like peptide-1 (GLP-1).

205 ed receptors (GPCRs) for glucagon (GluR) and glucagon-like peptide-1 (GLP-1R) are normally considered

206 .coli and purification of HepoK-incorporated glucagon-like peptide-1 (GLP1) is demonstrated.

207 visceral or cognitive threats that increase glucagon-like peptide-1 (GLP1) signaling from the caudal

208 together with the beneficial effects of the glucagon-like peptide-1 agonist exendin-4 in transgenic

209 odium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 agonists, and suggest how such d

210 vestigate the neuroprotective effects of the glucagon-like peptide-1 analog exenatide in resuscitated

211 Glucagon-like peptide-1 analogs are approved for type 2

212 trophy mice and further demonstrate that the glucagon-like peptide-1 analogue exendin-4, a well-toler

213 Liraglutide, a glucagon-like peptide-1 analogue, improves glycaemic con

214 f target engagement for clinical trials with glucagon-like peptide-1 analogues in multiple system atr

215 rolonging the half-life of incretins such as glucagon-like peptide-1 and gastric inhibitory peptide,

216 ates Ca(2+) , cAMP, and insulin responses to glucagon-like peptide-1 and its metabolites following il

217 n of a long-acting analog of the gut-hormone glucagon-like peptide-1 highlights the therapeutic poten

218 ced and density of endocrine cells secreting glucagon-like peptide-1 increased.

219 ffects of LiCl appear to be mediated through glucagon-like peptide-1 receptor (GLP-1R) activation, we

220 Here we hypothesize that manipulating glucagon-like peptide-1 receptor (GLP-1R) activity selec

221 ble incretin mimetic based upon the specific glucagon-like peptide-1 receptor (GLP-1R) agonist liragl

222 As the anorectic effects of glucagon-like peptide-1 receptor (GLP-1R) agonists are p

223 Glucagon-like peptide-1 receptor (GLP-1R) agonists reduc

224 Glucagon-like peptide-1 receptor (GLP-1R) agonists, wide

225 The glucagon-like peptide-1 receptor (GLP-1R) and the glucag

226 Therapeutic intervention to activate the glucagon-like peptide-1 receptor (GLP-1R) enhances gluco

227 We have shown previously that the incretin glucagon-like peptide-1 receptor (GLP-1R) internalizes f

228 Glucagon-like peptide-1 receptor (GLP-1R) is a class B G

229 The glucagon-like peptide-1 receptor (GLP-1R) is a key thera

230 The glucagon-like peptide-1 receptor (GLP-1R) is expressed i

231 first orally bioavailable and CNS penetrant glucagon-like peptide-1 receptor (GLP-1R) noncompetitive

232 tivated positive allosteric modulator of the glucagon-like peptide-1 receptor (GLP-1R), a class B GPC

233 The glucagon-like peptide-1 receptor (GLP-1R), a key pharmac

234 f intraduodenal metformin, and both duodenal glucagon-like peptide-1 receptor (Glp-1r)-protein kinase

235 hibits food-motivated behaviors through vCA1 glucagon-like peptide-1 receptor (GLP-1R).

236 o acid sequence of exendin-4 and targets the glucagon-like peptide-1 receptor (GLP-1R).

237 The glucagon-like peptide-1 receptor (GLP1R) is a class B G

238 smotic pump to give continuous delivery of a glucagon-like peptide-1 receptor agonist for 6-12 months

239 To determine the effects of the glucagon-like peptide-1 receptor agonist liraglutide add

240 Trial evidence shows that the glucagon-like peptide-1 receptor agonist liraglutide sig

241 e available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but

242 we evaluated the efficacy of a short-course glucagon-like peptide-1 receptor agonist therapy-specifi

243 als, including cholecystokinin, exendin-4 (a glucagon-like peptide-1 receptor agonist), amylin, and m

244 Albiglutide is a glucagon-like peptide-1 receptor agonist, a new class of

245 ons in the dipeptidyl peptidase-4 inhibitor, glucagon-like peptide-1 receptor agonist, and sodium-glu

246 Insulin regimens and specific glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ad

247 lucose-lowering medication occurred, and for glucagon-like peptide-1 receptor agonists (GLP-1 RAs; 3.

248 Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) are

249 Both glucagon-like peptide-1 receptor agonists and dipeptidyl

250 However, the distinction may be crucial for glucagon-like peptide-1 receptor agonists and other anti

251 es and consensus statements have recommended glucagon-like peptide-1 receptor agonists and sodium-glu

252 Glucagon-like peptide-1 receptor agonists and sodium-glu

253 Indeed, in several of the new statements, glucagon-like peptide-1 receptor agonists are suggested

254 More data regarding effects of glucagon-like peptide-1 receptor agonists in patients wi

255 to dramatic weight loss in combination with glucagon-like peptide-1 receptor agonists in preclinical

256 More recently, the glucagon-like peptide-1 receptor agonists liraglutide an

257 Although glucagon-like peptide-1 receptor agonists may be appropr

258 Glucagon-like peptide-1 receptor agonists may have addit

259 f dipeptidyl peptidase-4 inhibitors and some glucagon-like peptide-1 receptor agonists, at least in t

260 to micelles, and these micelles activate the glucagon-like peptide-1 receptor with a potency comparab

261 in vivo We further demonstrate that an ileal glucagon-like peptide-1 receptor-dependent neuronal netw

262 Given that PVT neurons express glucagon-like peptide-1 receptors (GLP-1R), which are cr

263 l literature suggests that targeting central glucagon-like peptide-1 receptors (GLP-1Rs) may represen

264 us of the stria terminalis (alBST) expresses glucagon-like peptide-1 receptors (GLP1Rs) and receives

265 for small non-peptide molecules to activate glucagon-like peptide-1 receptors.

266 Intriguingly, the central glucagon-like peptide-1 system defined in rodents is con

267 rs in hippocampal neurons to reduce (leptin, glucagon-like peptide-1) or increase (ghrelin) food inta

268 ucose cotransporter 2) inhibitors and GLP-1 (glucagon-like peptide-1) receptor agonists, has changed

269 Glucagon-like peptide-1-based (GLP-1-based) therapies im

270 lunted the body weight-lowering effects of a glucagon-like peptide-1-estrogen (GLP-1-estrogen) conjug

271 nt research has indicated a crucial role for glucagon-like peptide-1-producing preproglucagon (PPG) n

272 , we investigated the effects of G49, a dual glucagon-like peptide-1/glucagon receptor agonist, on NA

273 Dual-acting glucagon-like peptide-1/glucagon receptor agonists such

274 , insulin, C-peptide, and incretin hormones; glucagon-like peptide-1; and glucose-dependent insulinot

275 us of the solitary tract (cNTS) that produce glucagon-like peptide-1; published work in rodents indic

276 The FIGHT (Functional Impact of GLP-1 [glucagon-like peptide-1] for Heart Failure Treatment) tr

277 e effects of once-weekly exenatide (a GLP-1 [glucagon-like peptide-1] receptor agonist) versus placeb

278 haracterization, and clinical development of glucagon-like-peptide-1 (GLP-1) spans more than 30 years

279 Here, we investigated whether amylin- and glucagon-like-peptide-1 (GLP-1)-based combination therap

280 Postprandial glucagon-like peptide 17-36 (P = 0.784) and insulin (P =

281 Glucagon-like peptide 1 (GLP-1) and glucagon-like peptide 2 (GLP-2) are proglucagon derived

282 (PYY), glucagon-like peptide 1 (GLP-1), and glucagon-like peptide 2 (GLP-2) concentrations was great

283 Glucagon-like peptide-2 receptor agonists have therapeut

284 Glucagon-like peptide-2 was used in 17 patients.

285 Glucagon-like-peptide-2 (GLP-2) is an enteroendocrine ti

286 Glucagon-like peptide (GLP)-1 analogs such as liraglutid

287 Here I provide an overview of the actions of glucagon-like peptide (GLP)-1 and GLP-2, the two major e

288 ABSTACT: The gut hormone glucagon-like peptide (GLP)-1 and its analogues represen

289 IL6 increases production of glucagon-like peptide (GLP)-1 by L cells and alpha cells

290 eduction in circulating DPP4 and increase in Glucagon-like peptide (GLP)-1 levels as compared to the

291 Hypoglycemia can be avoided with glucagon-like peptide (GLP)-1 receptor agonists, which a

292 FFA3 colocalised with glucagon-like peptide (GLP)-1, whereas FFA2 colocalised

293 Growing evidence suggests that agonists of glucagon-like peptide (GLP-1) receptor exert neuroprotec

294 r suggested the presence of the gut hormone, glucagon-like peptide (GLP-1), in deep short axon cells

295 dase (DPP4i), which prevents the cleavage of glucagon-like peptide (GLP-1), to adult RIPCreER-EYFP mi

296 e effect of diacetyl on the satiety hormone, glucagon-like peptide (GLP-1), using the enteroendocrine

297 ncretin-based, antidiabetes therapies (i.e., glucagon-like peptide [GLP]-1 receptor agonists and dipe

298 The application of glucagon-like peptide one receptor agonists, specific PD

299 o-express several molecules including Glp1r (glucagon-like peptide one receptor) and manipulations of

300 Several glucagon-like peptide receptor agonists (GLP-1RA) and so